Sarecycline Seysara denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for sarecycline seysara are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Sarecycline (Seysara) as Duplicate Therapy

Blue Cross Blue Shield's duplicate-therapy denial means the plan's system flagged that you are already receiving — or recently received — another antibiotic it considers therapeutically equivalent for acne. Because sarecycline is a narrow-spectrum tetracycline-class antibiotic developed specifically for acne vulgaris, BCBS commonly flags it when a member has an active fill of doxycycline, minocycline, or another tetracycline on the same claim date.

### Why This Denial Is Appealable

Sarecycline received its own FDA approval on the basis of a distinct clinical profile from older tetracyclines, including its narrower antibacterial spectrum. If your prescriber chose sarecycline for a documented clinical reason — such as a history of gastrointestinal intolerance to another agent, prior treatment failure, or a specific patient characteristic — that clinical rationale distinguishes it from a true duplicate. BCBS must honor that distinction when it is adequately supported.

### Federal Appeal Framework

• Internal appeal: You have the right to a full internal appeal under ERISA §503 (employer plans) or ACA §2719 (individual/small-group plans). Submit within the plan's stated deadline (commonly 180 days from the denial notice).
• External review: If the internal appeal is denied, you may escalate to an independent external review organization under ACA §2719. The window to request external review is typically around four months from the final internal denial, though you should verify the exact deadline on your Explanation of Benefits.
• Expedited option: If your condition is urgent (active moderate-to-severe acne causing significant impact), request an expedited internal or external review, which requires a decision within days rather than weeks.

### Concrete Appeal Steps

1. Obtain the written denial letter and note the exact duplicate-therapy rationale cited. 2. Request a copy of BCBS's applicable formulary exception and duplicate-therapy coverage policy. 3. Ask your prescriber to document, in a medical-necessity letter, why sarecycline is clinically distinct from the flagged agent for your specific case. 4. Gather a medication history showing dates, doses, and documented outcomes or adverse effects of any prior tetracyclines tried. 5. Submit the internal appeal with all documentation and request a written decision within the plan's timeframe.

### Documentation to Gather

• Diagnosis confirmation: Dermatologist or prescriber chart notes confirming acne vulgaris diagnosis and severity grading.
• Prior-treatment history: Pharmacy records and chart notes showing prior antibiotic trials, with specific dates, durations, and documented reasons for discontinuation or failure.
• Clinical differentiation letter: Prescriber letter explaining why the currently approved agent is not therapeutically interchangeable for this patient.
• Criteria mapping: Copy each requirement from BCBS's duplicate-therapy policy and provide the corresponding chart fact that shows the agents are not equivalent in your case.

### Key Reminder

The exact eligibility criteria and any numeric thresholds that apply to your plan are found in BCBS's published medical or formulary coverage policy. Cross-reference every requirement in that document against your chart before submitting.